• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
Credit: Shutterstock
February 1, 2024 07:00 AM ESTUpdated 08:06 AM
Bioregnum

Biotech deal­mak­ing shows some signs of a turn­around. And the in­dus­try is keep­ing its fin­gers crossed

John Carroll

Editor & Founder

The big pan­dem­ic boom that fu­eled some crazy num­bers in biotech is long gone, as any­one in the in­dus­try who doesn’t re­side in a sen­so­ry …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

more like this

  • Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly July 10, 2025
  • Ab­b­Vie bags Cap­stan’s in vi­vo CAR-T work with $2.1B buy­out deal June 30, 2025
  • Fed­er­al­ly-fund­ed can­cer re­search comes to a per­ilous cross­roads June 9, 2025
TRENDING NOW

Prasad again over­rode FDA vac­cine re­view­ers, this time on Mod­er­na’s Covid shot for young kids

Mer­ck­'s PD-1xVEGF part­ner LaNo­va gets snapped up for $951M

The Trump ad­min­is­tra­tion dis­band­ed a new­born screen­ing pan­el. Ad­vo­cates now face a hard­er path

FDA ques­tions safe­ty, ef­fi­ca­cy of GSK's Blenrep in mul­ti­ple myelo­ma ahead of ad­comm

BMS warns against ‘in­dis­crim­i­nate use’ of rene­go­ti­a­tions as CMS plans next drug price talks

Up­dat­ed: Af­ter Phase 3 obe­si­ty suc­cess, Hen­grui plans Chi­na ap­proval fil­ing for Kail­era-part­nered drug

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times